Skip to content
value.today

Presbyopia Therapies, LLC

🇺🇸 Coronado, California, USAPharmaceuticalsFounded 2013
Total raised
$136 M
3 rounds on record
Latest round
$84 M
Mar 2023
First round on record
Jun 2016
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Presbyopia Therapies, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2023$84 MNo. 3$50 to $250 million

Presbyopia Therapies, LLC: Raise no. 3, Mar 2023

Investors in this round

27 investors had bought by the notice of Mar 10, 2023: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$84 M of $84 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Evert Schimmelpennink · Executive Officer, Director
  • Chris Dimitropoulos · Director
  • Clare Ozawa · Director
  • Frederic Guerard · Director
  • James McCollum · Director
  • Stefan Larson · Director
  • Zach Scheiner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Evert Schimmelpennink, President & CEO. Newest notice filed Mar 10, 2023. Read the notice at the SEC.

equitySEC
Oct 2020$49 MNo. 2$10 to $50 million

Presbyopia Therapies, LLC: Raise no. 2, Oct 2020

Investors in this round

45 investors had bought by the notice of Nov 22, 2022: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$49 M of $49 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Evert Schimmelpennink · Executive Officer, Director
  • Clare Ozawa · Director
  • Fred Guerard · Director
  • James McCollum · Director
  • Zach Scheiner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $46,999,991.15 new money; $251,192.63 conversion of debt; $1,751,164.25 upon the exercise of warrants”

Signed by Evert Schimmelpennink, President & CEO. Newest notice filed Nov 22, 2022 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Jun 2016$3 MNo. 1$2 to $10 million

Presbyopia Therapies, LLC: Raise no. 1, Jun 2016

Investors in this round

45 investors had bought by the notice of Jun 30, 2016: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$2,400
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Gerald Horn · Executive Officer · MANAGER
  • JAMES McCOLLUM · Executive Officer · MANAGER
  • Mark Lester · Executive Officer · MANAGER

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by JAMES McCOLLUM, Manager. Newest notice filed Jun 30, 2016. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Presbyopia Therapies, LLC chose not to state its revenue in its newest notice of a funding round (Mar 2023).

    SEC Form D · Mar 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Presbyopia Therapies, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Presbyopia Therapies, LLC
NameRoleNamed in
Evert SchimmelpenninkExecutive officerMar 2023
Gerald W. HornExecutive Officer and DirectorNov 2020
James W. McCollumExecutive Officer and DirectorNov 2020
Gerald HornMANAGERJun 2016
JAMES McCOLLUMMANAGERJun 2016
Mark LesterMANAGERJun 2016
Chris DimitropoulosDirectorMar 2023
Clare OzawaDirectorMar 2023
Evert SchimmelpenninkDirectorMar 2023
Frederic GuerardDirectorMar 2023
James McCollumDirectorMar 2023
Stefan LarsonDirectorMar 2023
Zach ScheinerDirectorMar 2023
Fred GuerardDirectorNov 2022
Gerald W. HornExecutive Officer and DirectorNov 2020
James W. McCollumExecutive Officer and DirectorNov 2020
Mark W. LesterDirectorNov 2020